Gemin X Biotechnologies Inc. Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
Published: May 15, 2007
MONTREAL--(BUSINESS WIRE)--Gemin X Biotechnologies Inc. announced today that a report published in the journal Blood demonstrated that its lead compound, obatoclax (GX15-070), induced cell death in vitro in Mantle Cell Lymphoma (MCL) cell lines and primary cells from 11 MCL patients. Obatoclax (GX15-070) is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis.